Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202987 | 0.88 | PTPN1 (0.53) | HSD11B1UCHL1PTPN1HDAC8 | |
| SCHEMBL19284689 | 0.85 | ACE (0.41) | ACEPOLB | |
| SCHEMBL30207832 | 0.85 | HSD11B1 (0.41) | HSD11B1UCHL1DDB1CRBNMAPK1 | |
| SCHEMBL19667491 | 0.85 | HSD11B1 (0.41) | HSD11B1UCHL1DDB1CRBNMAPK1 | |
| SCHEMBL66871 | 0.83 | ACE (0.59) | ACEPTPN1HDAC8POLB | |
| SCHEMBL29401053 | 0.83 | ACE (0.59) | ACEPTPN1HDAC8POLB | |
| SCHEMBL14067913 | 0.83 | ACE (0.59) | ACEPTPN1HDAC8POLB | |
| SCHEMBL66872 | 0.83 | ACE (0.59) | ACEPTPN1HDAC8POLB | |
| SCHEMBL29707284 | 0.83 | ACE (0.59) | ACEPTPN1HDAC8POLB | |
| SCHEMBL2080858 | 0.83 | ACE (0.59) | ACEPTPN1HDAC8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | HSD11B1 479/4885UCHL1 1373/4885ACE 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.